menu
Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics Announces First Quarter 2018 Financial Results

New CEO puts in vivo and ex vivo genome editing on parallel tracks towards the clinic  Company anticipates submitting its in vivo Investigational New Drug application by the end of 2019 for systemic lipid nanoparticle delivery of CRISPR/Cas9 to potentially cure transthyretin amyloidosis
Read More

Intellia Therapeutics Announces In Vivo and Ex Vivo Data Presentations at the American Society of Gene and Cell Therapy 21st Annual Meeting

CAMBRIDGE, Mass. , April 23, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, announced that two scientific abstracts have been accepted for presentation at the 21
Read More

Response to “Unexpected mutations after CRISPR–Cas9 editing in vivo"

Published in Nature Methods

Read More

Intellia Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results

Initiated final testing of safety and efficacy in non-human primates (NHP) for our lead program intended to treat patients with transthyretin amyloidosis (ATTR) Completed successful knockout editing in mice of the SERPINA1 gene that gives rise to liver complications in certain alpha-1 antitrypsin
Read More

Intellia Therapeutics to Present at March Healthcare Investor Conferences

CAMBRIDGE, Mass. , Feb. 28, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will participate at the following upcoming healthcare conferences in March: Tuesday,
Read More

Intellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 Genome Editing Using Lipid Nanoparticle (LNP) Delivery Technology

Intellia researchers achieved 97 percent reduction in serum transthyretin protein levels in mice through a single administration, with a durability of at least 12 months CRISPR/Cas9 administered via LNP was well-tolerated with no observed adverse events CRISPR/Cas9 components shown to be
Read More

Intellia Therapeutics to Present at February Healthcare Investor Conferences

CAMBRIDGE, Mass. , Jan. 31, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will present or host one-on-one meetings at the following upcoming healthcare
Read More

Intellia Therapeutics Names John Leonard, M.D., President and Chief Executive Officer

Dr. Leonard has successfully led the development and regulatory approval of breakthrough biopharmaceuticals Company’s pipeline continues to advance toward clinical development CAMBRIDGE, Mass. , Dec. 18, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
Read More

Intellia Therapeutics Announces New, Robust Genome Editing Data for Sickle Cell Disease at the American Society of Hematology Meeting

Data on ex vivo CRISPR/Cas9 genome-edited human hematopoietic stem cells shows increased production of fetal hemoglobin Approximately 80-95 percent editing was achieved in CD34+ cells Increased fetal hemoglobin levels were sustained for at least 16 weeks following transplant in mice ATLANTA , Dec.
Read More

Intellia Therapeutics to Present at November Healthcare Investor Conferences

CAMBRIDGE, Mass. , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will present at the following upcoming healthcare conferences in November: Tuesday,
Read More
RSS FEEDS
PRINT PAGE